WallStreetZenWallStreetZen

NASDAQ: CTSO
Cytosorbents Corp Stock Forecast, Predictions & Price Target

Analyst price target for CTSO

Based on 3 analysts offering 12 month price targets for Cytosorbents Corp.
Min Forecast
$1.00-15.97%
Avg Forecast
$4.67+292.18%
Max Forecast
$10.00+740.34%

Should I buy or sell CTSO stock?

Based on 3 analysts offering ratings for Cytosorbents Corp.
Strong Buy
Strong Buy
2 analysts 66.67%
Buy
0 analysts 0%
Hold
1 analysts 33.33%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their CTSO stock forecasts and price targets.

CTSO stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-10-01
lockedlocked$00.00+00.00%2024-08-14
lockedlocked$00.00+00.00%2024-05-15

1 of 1

Forecast return on equity

Is CTSO forecast to generate an efficient return?
Company
-6.5%
Industry
25.35%
Market
49.24%
CTSO's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is CTSO forecast to generate an efficient return on assets?
Company
-2.04%
Industry
13.51%
CTSO is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

CTSO earnings per share forecast

What is CTSO's earnings per share in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
-$0.32
Avg 2 year Forecast
-$0.15
Avg 3 year Forecast
$0.02

CTSO revenue forecast

What is CTSO's revenue in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
$39.5M+6.36%
Avg 2 year Forecast
$46.6M+25.45%
Avg 3 year Forecast
$52.9M+42.26%
CTSO's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

CTSO revenue growth forecast

How is CTSO forecast to perform vs Medical Devices companies and vs the US market?
Company
12.61%
Industry
7.23%
Market
9.63%
CTSO's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
CTSO's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

CTSO vs Medical Device Stocks

TickerPricePrice TargetUp/downsideConsensus
CTSO$1.19$4.67+292.18%Strong Buy
COCH$3.31$8.75+164.35%Buy
DHAI$1.61N/AN/A
TELA$2.70$10.00+270.37%Strong Buy
NSPR$2.64$4.50+70.45%Strong Buy

Cytosorbents Stock Forecast FAQ

Is Cytosorbents Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: CTSO) stock is to Strong Buy CTSO stock.

Out of 3 analysts, 2 (66.67%) are recommending CTSO as a Strong Buy, 0 (0%) are recommending CTSO as a Buy, 1 (33.33%) are recommending CTSO as a Hold, 0 (0%) are recommending CTSO as a Sell, and 0 (0%) are recommending CTSO as a Strong Sell.

If you're new to stock investing, here's how to buy Cytosorbents stock.

What is CTSO's earnings growth forecast for 2024-2026?

(NASDAQ: CTSO) Cytosorbents's forecast annual earnings growth rate of N/A is not forecast to beat the US Medical Devices industry's average forecast earnings growth rate of 27.71%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.7%.

Cytosorbents's earnings in 2024 is -$25,529,434.On average, 3 Wall Street analysts forecast CTSO's earnings for 2024 to be -$17,237,860, with the lowest CTSO earnings forecast at -$17,961,774, and the highest CTSO earnings forecast at -$15,784,589. On average, 3 Wall Street analysts forecast CTSO's earnings for 2025 to be -$7,984,825, with the lowest CTSO earnings forecast at -$15,240,293, and the highest CTSO earnings forecast at -$2,177,185.

In 2026, CTSO is forecast to generate $816,444 in earnings, with the lowest earnings forecast at -$1,088,592 and the highest earnings forecast at $2,721,481.

What is CTSO's revenue growth forecast for 2024-2026?

(NASDAQ: CTSO) Cytosorbents's forecast annual revenue growth rate of 12.61% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 7.23%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.63%.

Cytosorbents's revenue in 2024 is $37,159,990.On average, 3 Wall Street analysts forecast CTSO's revenue for 2024 to be $2,151,221,753, with the lowest CTSO revenue forecast at $2,042,199,230, and the highest CTSO revenue forecast at $2,249,576,071. On average, 3 Wall Street analysts forecast CTSO's revenue for 2025 to be $2,537,291,026, with the lowest CTSO revenue forecast at $2,421,573,660, and the highest CTSO revenue forecast at $2,708,417,742.

In 2026, CTSO is forecast to generate $2,877,421,703 in revenue, with the lowest revenue forecast at $2,848,846,154 and the highest revenue forecast at $2,905,997,252.

What is CTSO's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: CTSO) forecast ROA is -2.04%, which is lower than the forecast US Medical Devices industry average of 13.51%.

What is CTSO's Price Target?

According to 3 Wall Street analysts that have issued a 1 year CTSO price target, the average CTSO price target is $4.67, with the highest CTSO stock price forecast at $10.00 and the lowest CTSO stock price forecast at $1.00.

On average, Wall Street analysts predict that Cytosorbents's share price could reach $4.67 by Oct 1, 2025. The average Cytosorbents stock price prediction forecasts a potential upside of 292.18% from the current CTSO share price of $1.19.

What is CTSO's Earnings Per Share (EPS) forecast for 2024-2026?

(NASDAQ: CTSO) Cytosorbents's current Earnings Per Share (EPS) is -$0.53. On average, analysts forecast that CTSO's EPS will be -$0.32 for 2024, with the lowest EPS forecast at -$0.33, and the highest EPS forecast at -$0.29. On average, analysts forecast that CTSO's EPS will be -$0.15 for 2025, with the lowest EPS forecast at -$0.28, and the highest EPS forecast at -$0.04. In 2026, CTSO's EPS is forecast to hit $0.02 (min: -$0.02, max: $0.05).

What is CTSO's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: CTSO) forecast ROE is -6.5%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.